FDA panel to discuss Aranesp data

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Oct. 18 to discuss the Phase III TREAT trial of Aranesp darbepoetin alfa from Amgen Inc. (NASDAQ:AMGN) to treat chronic kidney dise...